> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Organon's Third-Quarter Adjusted Earnings Slip To $0.94 A Share, And There Is No Earnings Call
- URL: https://www.bullished.co/organons-third-quarter-adjusted-earnings-slip-to-0-94-a-share-and-there-is-no-earnings-055f0e59/
- Published: 2026-10-30T12:36:00.000Z
- Updated: 2026-10-30T12:36:00.000Z
- Description: Adjusted EBITDA fell to $502 million from $518 million as the pending Sun Pharmaceutical merger replaced the usual release and call.
- Author: Matteo Parrino
- Tags: Deals, OGN, Industry: Healthcare

[Organon](https://www.bullished.co/tag/ogn/), the prescription-medicine maker behind the Nexplanon contraceptive implant, posted adjusted diluted earnings of [$0.94 a share](https://www.sec.gov/Archives/edgar/data/0001821825/000110465926120423/tm2628576d1%5Fex99-1.htm?ref=bullished.co) for the third quarter, down from $1.01 a year earlier. The company put the numbers out in an [8-K filed Friday](https://www.sec.gov/Archives/edgar/data/0001821825/000110465926120423/tm2628576d1%5F8k.htm?ref=bullished.co) rather than an earnings release or call, which it suspended because of its pending merger with Sun Pharmaceutical Industries Limited.

## Adjusted measures slip, reported ones hold

Adjusted EBITDA, which strips out one-time items, stock pay and similar costs, came to $502 million in the quarter, against $518 million a year earlier. The adjusted EBITDA margin was 31.9%, versus 32.3%.

Adjusted net income was $256 million, against $263 million. Adjusted gross margin was 59.6%, down from 60.3%.

Standard-accounting results moved the other way or held flat. Net income was $164 million versus $160 million, and gross margin rose to 55.2% from 53.5%. Standard diluted earnings per share were $0.60, against $0.61.

The gap between the two views narrowed: adjustments added $0.34 a share this quarter, against $0.40 a year earlier.

## Nine months show a sharper decline

Over the first nine months, adjusted net income fell to $674 million from $789 million. Adjusted EBITDA dropped to $1.378 billion from $1.524 billion, and its margin to 30.0% from 32.4%.

Adjusted diluted earnings per share for the nine months were $2.51, against $3.03\. Standard earnings per share rose to $1.56 from $1.50.

The nine-month adjusted figures exclude an $81 million gain from the Jada divestiture, which is removed from the total.

## Deal costs and manufacturing exits

Other costs added back in the quarter included $19 million tied to the pending Sun Pharmaceutical transaction. For the nine months, that figure was $30 million, plus $17 million from an unfavorable resolution of a working-capital matter on the Dermavant acquisition.

Manufacturing network costs, from exiting supply agreements with Merck, were $23 million in the quarter, against $46 million a year earlier.

Organon sells more than 70 products in women's health and general medicines. In 2025, its revenue was $6.2 billion, about 74% of it from outside the United States, according to its annual report.

Organon filed its full quarterly report with the SEC on Friday, the same day as the supplemental adjusted figures.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Organon & Co. (OGN)](https://www.sec.gov/Archives/edgar/data/0001821825/000110465926120423/tm2628576d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628576d1\_ex99-1.htm — Organon & Co. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001821825/000110465926120423/tm2628576d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR

### More on Organon

- [Organon Puts A Name On Its Supply Problem, Pegging The Third-Quarter Revenue Hit At Under 2%](https://www.bullished.co/organon-puts-a-name-on-its-supply-problem-pegging-the-third-quarter-revenue-hit-at-under-2-5e235491/)

[All Organon (OGN) coverage →](https://www.bullished.co/tag/ogn/)